---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056902"
form_type: "8-K"
ticker: null
cik: "0001564824"
company_name: "Allakos Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:53:28.409081+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Allakos Q1 net loss $71.1M ($0.81/sh); cash burn $31.5M; impairment $27.3M

## Summary
- Net loss $71.1M vs $42.4M YoY; diluted EPS $(0.81) vs $(0.49); non-cash impairment charge $27.3M from lirentelimab halt.
- Cash, equivalents, investments $139.3M at March 31; net decrease $31.5M in Q1; runway extended into mid-2026.
- Restructuring costs for lirentelimab closeout ~$30M total; $12M paid in Q1, remaining ~$18M expected Q2-Q3 2024.
- Completed Phase 1 dosing of AK006 (IV and SC) in healthy volunteers; initiated Phase 1 trial in chronic spontaneous urticaria.
- Upcoming milestones: Phase 1 healthy volunteer data Q2/Q3 2024; CSU topline data year-end 2024.

## SEC filing metadata
- accession: 0000950170-24-056902
- form_type: 8-K
- cik: 0001564824
- company_name: Allakos Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1564824/000095017024056902/0000950170-24-056902-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1564824/000095017024056902/allk-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056902
- JSON: https://secwatch.observer/filing/0000950170-24-056902.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056902.txt

## Key facts
- Earnings Releases
  Allakos Inc. updated its the first quarter ended March 31, 2024 guidance (reaffirmed).
  - Period: the first quarter ended March 31, 2024
  - Guidance: reaffirmed
  - Result: reported results
  source text: On May 9, 2024, Allakos Inc. (the “Company”) issued a press release reporting its financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1564824/000095017024056902/0000950170-24-056902-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.